IRIS
AVOLIO, CARLO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 4.697
EU - Europa 3.756
AS - Asia 2.661
Continente sconosciuto - Info sul continente non disponibili 1.129
SA - Sud America 511
AF - Africa 58
OC - Oceania 11
Totale 12.823
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.603
SG - Singapore 1.027
IE - Irlanda 889
CN - Cina 800
RU - Federazione Russa 569
UA - Ucraina 486
IT - Italia 455
BR - Brasile 411
SE - Svezia 389
HK - Hong Kong 289
DE - Germania 272
FR - Francia 257
VN - Vietnam 176
FI - Finlandia 155
GB - Regno Unito 98
IN - India 98
BD - Bangladesh 68
TR - Turchia 68
CA - Canada 42
AR - Argentina 40
BE - Belgio 39
NL - Olanda 28
AT - Austria 25
MX - Messico 21
ES - Italia 20
PL - Polonia 19
ID - Indonesia 18
ZA - Sudafrica 17
IQ - Iraq 16
EU - Europa 15
VE - Venezuela 15
EC - Ecuador 14
JP - Giappone 14
IR - Iran 13
PK - Pakistan 12
CL - Cile 10
CR - Costa Rica 10
CZ - Repubblica Ceca 10
AU - Australia 8
PT - Portogallo 8
CO - Colombia 7
TN - Tunisia 7
JO - Giordania 6
LT - Lituania 6
MA - Marocco 6
SC - Seychelles 6
UZ - Uzbekistan 6
AE - Emirati Arabi Uniti 5
HU - Ungheria 5
PH - Filippine 5
PY - Paraguay 5
SA - Arabia Saudita 5
XK - ???statistics.table.value.countryCode.XK??? 5
BO - Bolivia 4
DZ - Algeria 4
HN - Honduras 4
JM - Giamaica 4
MY - Malesia 4
CH - Svizzera 3
EG - Egitto 3
GT - Guatemala 3
HR - Croazia 3
NP - Nepal 3
PE - Perù 3
RO - Romania 3
SN - Senegal 3
TH - Thailandia 3
AL - Albania 2
AM - Armenia 2
AO - Angola 2
AZ - Azerbaigian 2
BH - Bahrain 2
DO - Repubblica Dominicana 2
EE - Estonia 2
ET - Etiopia 2
GR - Grecia 2
KE - Kenya 2
KR - Corea 2
KZ - Kazakistan 2
LB - Libano 2
LK - Sri Lanka 2
LU - Lussemburgo 2
MN - Mongolia 2
MU - Mauritius 2
PS - Palestinian Territory 2
UY - Uruguay 2
AD - Andorra 1
BA - Bosnia-Erzegovina 1
BB - Barbados 1
BG - Bulgaria 1
BS - Bahamas 1
BY - Bielorussia 1
BZ - Belize 1
CI - Costa d'Avorio 1
CM - Camerun 1
DK - Danimarca 1
GE - Georgia 1
GP - Guadalupe 1
KG - Kirghizistan 1
KI - Kiribati 1
Totale 11.697
Salva come PNG Salva come JPEG
Città #
San Jose 908
Dublin 888
Chandler 403
Singapore 395
Jacksonville 328
Ashburn 317
Nyköping 286
Hong Kong 284
Dearborn 269
Beijing 224
Dallas 167
Santa Clara 149
Nanjing 145
Council Bluffs 141
Lauterbourg 111
Princeton 91
Wilmington 90
Columbus 83
Moscow 77
The Dalles 77
Munich 76
Helsinki 73
New York 68
Nanchang 65
Woodbridge 60
Ann Arbor 59
Ho Chi Minh City 52
San Mateo 51
Los Angeles 47
Hanoi 40
Brussels 39
Boardman 37
Des Moines 33
Jiaxing 33
São Paulo 33
Turku 33
Shenyang 30
Foggia 29
Nuremberg 26
Frankfurt am Main 25
Milan 25
Tianjin 25
Rome 22
Cedar Knolls 21
Changsha 21
Hebei 21
Naples 21
Chicago 19
Kunming 19
Bari 17
Guangzhou 15
Zhengzhou 15
Hangzhou 14
Rio de Janeiro 14
Seattle 14
Warsaw 14
Tokyo 13
Orem 12
San Severo 12
Falkenstein 11
Hilden 11
Ningbo 11
Norwalk 11
Redwood City 11
Taizhou 11
Brooklyn 10
Curitiba 10
Jinan 10
London 10
San Francisco 10
Belo Horizonte 9
Bologna 9
Brasília 9
Kocaeli 9
Montreal 9
Pimonte 9
Toronto 9
Assago 8
Auburn Hills 8
Boston 8
Buffalo 8
Fortaleza 8
Johannesburg 8
Lanzhou 8
Ottawa 8
San José 8
Atlanta 7
Baghdad 7
Bắc Ninh 7
Falls Church 7
Haiphong 7
Jakarta 7
Mexico City 7
Pune 7
Vienna 7
Amman 6
Biên Hòa 6
Hanover 6
Madrid 6
Manchester 6
Totale 7.020
Salva come PNG Salva come JPEG
Nome #
Do patients and referral centers characteristics influence multiple sclerosis phenotypes? Results from the Italian multiple sclerosis and related disorders register 208
Serum Soluble Intercellular Adhesion Molecule-1 in MS: relation to clinical and Gd-MRI activity, and to rIFNβ-1b treatment. 156
Serial immunoprecipitation assays for interferon-(IFN)-beta antibodies in multiple sclerosis patients. 148
Analisi fenotipica di linfociti T di pazienti con Sclerosi multipla (SM) nel sangue periferico ed in coltura con e senza aggiunta di mitogeni 148
Comparison of Clinical and demographic features between affected pairs of Italian Multiple Sclerosis Multiplex families; relation to Tumor Necrosis Factor genomic polymorphisms. 146
Defining the electroclinical phenotype and outcome of PCDH19‐related epilepsy: A multicenter study 146
Anti-Inflammatory and Anti-Oxidant Effect of Dimethyl Fumarate in Cystic Fibrosis Bronchial Epithelial Cells 146
Changes of serum ICAM-1 and MMP-9 induced by rIFNbeta-1b treatment in relapsing-remitting MS. 141
The epilepsy phenotype in adult patients with intellectual disability and pathogenic copy number variants 141
Intravenous lacosamide in seizure emergencies: Observations from a hospitalized in-patient adult population. 140
Adhesion molecules and matrix metalloproteinases in MS: effects induced by Interferon beta. 139
Espressione di LFA-1 su linfociti memoria CD4+CD45RO+ si sangue periferico nella Sclerosi Multipla remittente: effetti indotti dall’ IFN b-1a. 139
Consensus recommendations of the Italian Association for Neuroimmunology for immunochemical cerebrospinal fluid examination. 137
Analisi liquorale per la diagnosi ed il follow-up di malattie infiammatorie del SNC. 137
CSF and serum soluble adhesion molecules in Multiple Sclerosis 136
Italian cohort of Lafora disease: Clinical features, disease evolution, and genotype-phenotype correlations 131
Usefulness of a standardized method for collecting anamnestic data in multiple sclerosis (MS). 130
Disease duration, relapse rate and clinical course in Multiple Sclerosis. Relation to IgG production within the blood-brain barrier. 130
Design of a European multicenter study dedicated to the evaluation of the EDMUS system: EVALUED. 130
Age-Related Disability in Multiple Sclerosis. 129
Between-laboratory variability in oligoclonal IgG band numbering. 129
T regulatory cells are markers of disease activity in multiple sclerosis patients. 129
Combination treatment of Glatiramer Acetate and Minocycline affects phenotype expression of blood monocyte-derived dendritic cells in Multiple Sclerosis patients. 128
European Validation of a Standardized Clinical Description of Multiple Sclerosis. 126
L’ esame del liquor (CSF) nella diagnosi di Sclerosi Multipla (SM) 126
New Insights Into Immune Cell-Derived Extracellular Vesicles in Multiple Sclerosis. 124
Counting of peripheral extracellular vesicles in Multiple Sclerosis patients by an improved nanoplasmonic assay and dynamic light scattering 123
Differential regulation of membrane bound and soluble ICAM 1 in human endothelium and blood mononuclear cells: effects of interferon beta-1a. 122
Intrathecal IgG synthesis and clinical course in Multiple Sclerosis 122
Tremor, sensory-motor polyneuropathy and cerebral gliosis in klinefelter's syndrome 121
Multivariate analysis of predictive factors of multiple sclerosis course with a validated method to assess clinical events. 121
Disease-Modifying Treatments and Time to Loss of Ambulatory Function in Patients With Primary Progressive Multiple Sclerosis 120
Wernicke's encephalopathy following reduced food intake due to depressive disorders. 120
Soluble Intercellular Adhesion Molecule-1 in serum and cerebrospinal fluid (CSF) of clinically active relapsing-remitting multiple sclerosis: correlation with Gd-DTPA Magnetic Resonance Imaging enhancement and CSF findings. 119
Effects of rIFNbeta-1b on serum circulating ICAM-1 in relapsing remitting multiple sclerosis and on the membrane-bound ICAM-1 expression on brain microvascular endothelial cells. 118
Late-onset Leber hereditary optic neuropathy mimiking Susac’s syndrome 117
Serum MMP-9/TIMP-1 and MMP-2/TIMP-2 ratios in Multiple Sclerosis: relationships with different MRI measures of disease activity during IFN-beta-1a treatment. 116
First-aid management of tonic-clonic seizures among healthcare personnel: A survey by the Apulian section of the Italian League Against Epilepsy 116
Interferon beta in relapsing / remitting multiple sclerosis: an independent postmarketing study in southern Italy. 115
Soluble Intercellular adhesion molecule-1 (sICAM-1) in serum and cerebrospinal fluid of demyelinating diseases of the central and the peripheral nervous system. 115
Epstein–Barr virus (EBV) and multiple sclerosis association: EBV has a primary or secondary role? 114
Post-marketing of disease modifying drugs in multiple sclerosis: An exploratory analysis of gender effect in interferon beta treatment. 114
Serum MMP-2 and MMP-9 are elevated in different Multiple Sclerosis subtypes. 114
Soluble Intercellular Adhesion Molecule-1 (sICAM-1) nel siero e liquor di pazienti con sclerosi multipla remittente clinicamente attiva: correlazioni con lesioni RMI che assumono gadolinio e con parametri liquorali 114
Prognostic indicators in pediatric clinically isolated syndrome. 114
MicroRNAs 181a and 125a are highly expressed in naïve RRMS: a pilot case-control study 113
Exit Strategies in Natalizumab-Treated RRMS at High Risk of Progressive Multifocal Leukoencephalopathy: a Multicentre Comparison Study 113
Krebs cycle derivatives, dimethyl fumarate and itaconate, control metabolic reprogramming in inflammatory human microglia cell line 111
Il ruolo dell’ esame del liquor 111
Effect of fingolimod action on the release of monocyte-derived microvesicles in multiple sclerosis patients. 110
An Italian multicentre study of perampanel in progressive myoclonus epilepsies 110
Quantitation of intrathecal measles virus IgG antibody synthesis rate: Subacute sclerosing panencephalitis and multiple sclerosis. 109
Immune and central nervous system-related miRNAs expression profiling in monocytes of multiple sclerosis patients. 109
Detection of disability worsening in relapsing-remitting multiple sclerosis patients: a real-world roving Expanded Disability Status Scale reference analysis from the Italian Multiple Sclerosis Register 109
LFA-1 expressing CD4+CD45RO+ peripheral blood T-lymphocytes in RR MS: effects induced by rIFNbeta-1a. 108
Intrathecal synthesis of matrix metalloproteinase-9 in patients with multiple sclerosis: implication for pathogenesis. 106
Glatiramer Acetate in Multiple Sclerosis: a review 106
Pharmacological treatment of depression in Alzheimer's disease: A challenging task 106
No evidence of disease activity (NEDA-3) and disability improvement after alemtuzumab treatment for multiple sclerosis: a 36-month real-world study 106
Usefulness of a standardised collection of disease events for clinical studies in Multiple Sclerosis. 105
Brivaracetam in Absence Status Epilepticus 104
Glatiramer Acetate induces pro-apoptotic mechanisms involving Bcl-2, Bax and Cyt-c in peripheral lymphocytes from Multiple Sclerosis patients. 101
Effetti antinfiammatori dell’ Interferone beta-1b ricombinante nella Sclerosi Multipla: studio longitudinale dei livelli sierici della forma solubile di Intercellular Adhesion Molecule-1 (sICAM-1) e dei subsets linfocitari 101
P2X7 purinergic receptor on monocytes of patients with Multiple Sclerosis: effects of Glatiramer Acetate immune modulation 101
Faciobrachial dystonic seizures expressed as epileptic spasms, followed by focal seizures in anti-LGI1 encephalitis: a video-polygraphic study. 101
Perceptive and Subjective Evaluation of Speech Disorders in Parkinson's Disease 101
IMMUNOSENESCENCE AND MULTIPLE SCLEROSIS: PROGNOSTIC AND THERAPEUTIC IMPLICATIONS 99
Comparing STRATIFY JCV™ DxSelect™ and IMMUNOWELL™ JCV IgG Tests in RRMS to Assess PML Risk 99
How the cognitive reserve interacts with β-amyloid deposition in mitigating FDG metabolism: An observational study. 99
From Cannabis sativa to Cannabidiol: Promising Therapeutic Candidate for the Treatment of Neurodegenerative Diseases 98
Autoimmune liver disease and multiple sclerosis: state of the art and future perspectives 98
Real world comparison of teriflunomide and dimethyl fumarate in naïve relapsing multiple sclerosis patients: Evidence from the Italian MS register 97
Retrospectively acquired cohort study to evaluate the long-term impact of two different treatment strategies on disability outcomes in patients with relapsing multiple sclerosis (RE.LO.DI.MS): data from the Italian MS Register. 95
Association of Loneliness with Functional and Cognitive Status in Minor and Major Neurocognitive Disorders 94
Fisiopatologia della risposta immunitaria nel compartimento liquorale. XXXVII Congress of the Italian Neurological Society, Bari 14-18 October 2006. 93
Interaction between Cognitive Reserve and Biomarkers in Alzheimer Disease 93
Is It Time for Ocrelizumab Extended Interval Dosing in Relapsing Remitting MS? Evidence from An Italian Multicenter Experience During the COVID-19 Pandemic 92
The effect of quarantine due to Covid-19 pandemic on seizure frequency in 102 adult people with epilepsy from Apulia and Basilicata regions, Southern Italy 92
Mesenchymal Stem Cell-Derived Extracellular Vesicles and Their Therapeutic Use in Central Nervous System Demyelinating Disorders 91
Editorial: Immunosenescence and multiple sclerosis: Prognostic and therapeutic implications 90
Fluctuations of MS births and UV-light exposure. 90
Weight loss and decubitus duodenal ulcer in Parkinson's disease treated with levodopa-carbidopa intestinal gel infusion. 88
The Italian multiple sclerosis register 88
Molecular Characterization of Peripheral Extracellular Vesicles in Clinically Isolated Syndrome: Preliminary Suggestions from a Pilot Study 86
IgG and IgM antibodies to the refolded MOG(1-125) extracellular domain in humans. 85
Monocytes P2X7 purinergic receptor is modulated by glatiramer acetate in multiple sclerosis. 84
Metabolic reprogramming in inflammatory microglia indicates a potential way of targeting inflammation in Alzheimer's disease 83
Risk of multiple sclerosis relapses when switching from fingolimod to cell-depleting agents: the role of washout duration 83
An Association of Framingham Risk Score with Patient Determined Disease Steps in a Cohort of Relapsing-Remitting Multiple Sclerosis Patients: An Italian Real-World Monocentric Experience 82
Multiple Sclerosis Treatments Affect Monocyte-Derived Microvesicle Production. 82
Stopping Interferon Beta 1b Does Not Influence the Risk of Disability Accrual in Non-Active SPMS: Results from an Italian Real-World Study 80
Evaluating Cognitive Outcomes in Multiple Sclerosis: Real-World Impact of Ozanimod on Processing Speed Using BICAMS 79
Treatment with metformin in twelve patients with Lafora disease 77
Guillain-Barré syndrome as only manifestation of COVID-19 infection 77
First-line therapies in Late Onset Multiple Sclerosis: an Italian registry study 77
Unraveling the inflammation-degeneration tangle in early MS: preliminary insights from ferritin, neurogranin, TREM2, and retinal ganglion cell layer 73
Synergistic interaction of fatty acids and oxysterols impairs mitochondrial function and limits liver adaptation during nafld progression (Q1 WoS) 71
Ocrelizumab Extended Interval Dosing in Primary Progressive Multiple Sclerosis: An Italian Experience 70
Personality Traits and Fatigue in Multiple Sclerosis: A Narrative Review 70
Lactobacilli Cell-Free Supernatants Modulate Inflammation and Oxidative Stress in Human Microglia via NRF2-SOD1 Signaling 70
Totale 11.021
Salva come PNG Salva come JPEG
Categoria #
all - tutte 64.373
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 64.373
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022470 0 12 16 15 41 10 19 30 66 56 40 165
2022/20232.491 198 129 105 157 119 191 18 144 1.049 117 186 78
2023/2024389 65 55 23 24 43 69 32 17 4 8 18 31
2024/20252.252 64 37 55 54 57 247 194 174 483 156 247 484
2025/20264.111 222 446 395 524 223 191 749 376 350 249 131 255
2026/2027370 132 238 0 0 0 0 0 0 0 0 0 0
Totale 12.823